Tuesday December 10, 2019
Home India Shaw: India n...

Shaw: India needs to up its game in Science and Technology

0
//

Bengaluru: Biocon chairperson Kiran Mazumdar Shaw stated on Tuesday that India continues to be a sub-optimal country when it comes to investing in the science and technology sector.

Biocon Limited is an Indian bio-pharmaceutical company based in Bangalore, India headed by Indian entrepreneur Kiran Mazumdar Shaw. Shaw was awarded the Othmer Gold Medal for her outstanding contributions to the progress of science and chemistry in 2014.

“Amongst all the countries who invest in science and technology, we are at a sub-optimal level,” said Shaw at Bangalore India Bio.

Referring to South Korea, which is leading investments in science and technology, she said: “I think India needs to basically up its game in science and technology through greater investments.”

She requested the government to increase science and technology investments as it is the future of India.

According to the Biocon chairperson, India needs to invest $5 billion in biotechnology to achieve the target of growing the sector to $100 billion by 2025.

“Today biotechnology is a $11 billion sector, growing at a compounded annual growth rate of 20 percent. We also are aspiring to be a $100 billion sector by 2025,” she said.

Addressing the 16th edition of Bangalore India Bio, Union Science and Technology Minister Harsh Vardhan said: “A lot has been achieved in this field in the last 30 years. Bangalore is not only the hub of bio-tech, it is also the destination of all scientists in India. It is the science hub for India.”

He said the government allotted Rs 10,000 to support entrepreneurs and startups in biotechnology.

Scheduled from February 9-11, Bangalore India Bio will cover a spectrum of activities which include an international trade show, keynote talks and multi-track conferences among others.

As many as 25 sessions featuring 110 speakers will deliberate on topics like making tomorrow’s medicine, oncology and precision medicine, rare diseases and orphan drugs, agribiotechnology, synthetic bio-fuels and others. (IANS)

Next Story

Biocon Reduces Retail Price of its Recombinant Human Insulin 50% in Low-and-Middle Income Countries

"Price should not be the reason to choose between life and death," said UNAIDS executive director Gunilla Carlsson on the occasion

0
Biocon, Retail, Price
Biocon chairperson Kiran Mazumdar-Shaw announced the reduction in the cost of life-saving insulin at the joint United Nations Progamme on HIV and AIDS (UNAIDS) health innovation exchange meeting on Wednesday on the margins of the UN General Assembly in New York. Pixabay

Biocon Biologics reduced the retail price of its recombinant human insulin 50 per cent in the low-and-middle income countries, the biotech major said on Friday.

“We will offer the anti-diabetic drug at 10 cents for 40 units of insulin required per patient per day in low-and-middle income countries,” said the city-based bio-pharma firm in a statement here.

Biocon chairperson Kiran Mazumdar-Shaw announced the reduction in the cost of life-saving insulin at the joint United Nations Progamme on HIV and AIDS (UNAIDS) health innovation exchange meeting on Wednesday on the margins of the UN General Assembly in New York.

“Price should not be the reason to choose between life and death,” said UNAIDS executive director Gunilla Carlsson on the occasion.

Biocon, Retail, Price
Biocon Biologics reduced the retail price of its recombinant human insulin 50 per cent in the low-and-middle income countries, the biotech major said on Friday. Pixabay

Over 400 million people worldwide are affected by diabetes. Evidence shows as they live longer, many people with HIV and on HIV treatment are becoming susceptible to non-communicable diseases.

“AIDS activism has led to reducing the price of life-saving medicines and saving millions of lives. Our universal health coverage movement is benefiting from the lessons learned by the AIDS response,” said Carlsson on the occasion.

The Mumbai-based Wadhwani Institute for Artificial Intelligence, an independent, non-profit research institute and global hub, is developing artificial intelligence solutions for social good.

“The Institute has committed to set up a centre of excellence to leverage the use of artificial intelligence for global health,” said the statement.

Also Read- NRIs Cheered for PM Modi

The IoT has opened up huge possibilities in health: when connected to the Internet, ordinary medical devices can collect more data, give insight into symptoms and trends, enable remote care and give people more control over their lives and quality of treatment.

Thought-Focus, a technology services firm, will provide access to its Internet of Things (IoT) platform to serve as an affordable, reliable and efficient way to build and extend IoT solutions for transportation, logistics, manufacturing and utilities related to health-care services.

“The IoT has opened up huge possibilities in health. When connected to the Internet, ordinary medical devices can collect more data, give insight into symptoms and trends, enable remote care and give people control over their lives and quality of treatment,” said the statement.

Biocon, Retail, Price
“We will offer the anti-diabetic drug at 10 cents for 40 units of insulin required per patient per day in low-and-middle income countries,” said the city-based bio-pharma firm in a statement here. Pixabay

Zenysis, a technology firm, said it was investing $ 3.5 million to implement data pilots in five countries over the next three years for helping countries to make evidence-based decisions in rolling out universal health coverage and prioritizing investments in health systems.

Also Read- Positive Social Relationships Help Increase Self-Esteem

“The private sector has a key role to play in advancing the sustainable development goals,” added Ms Carlsson. (IANS)